PMID- 24760109
OWN - NLM
STAT- MEDLINE
DCOM- 20150416
LR  - 20240322
IS  - 1573-2592 (Electronic)
IS  - 0271-9142 (Print)
IS  - 0271-9142 (Linking)
VI  - 34 Suppl 1
IP  - 0 1
DP  - 2014 Jul
TI  - Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and 
      neuropreservatory effects in preclinical models of Alzheimer's disease.
PG  - S80-5
LID - 10.1007/s10875-014-0020-9 [doi]
AB  - Intravenous immunoglobulin (IVIG) has shown limited promise so far in human 
      clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive 
      preclinical work in animals and human brain cultures support the notion that the 
      therapy remains potentially efficacious. Here, we elaborate on IVIG 
      neuropreservation by demonstrating that IVIG protects human primary neurons 
      against oxidative stress in vitro and that IVIG preserves antioxidant defense 
      mechanisms in vivo. Based on these results, we propose the following 
      translational impact: If the dosage and treatment conditions are adequately 
      optimized, then IVIG treatment could play a significant role in preventing and/or 
      delaying the progression of neurodegenerative diseases, such as AD. We suggest 
      that IVIG warrants further investigation to fully exploit its potential as an 
      anti-oxidant, neuroprotective and synapto-protecting agent.
FAU - Counts, Scott E
AU  - Counts SE
AD  - Department of Translational Science and Molecular Medicine, Michigan State 
      University, 333 Bostwick Ave NE, Grand Rapids, MI, 49503, USA, 
      scott.counts@hc.msu.edu.
FAU - Ray, Balmiki
AU  - Ray B
FAU - Mufson, Elliott J
AU  - Mufson EJ
FAU - Perez, Sylvia E
AU  - Perez SE
FAU - He, Bin
AU  - He B
FAU - Lahiri, Debomoy K
AU  - Lahiri DK
LA  - eng
GR  - P01 AG014449/AG/NIA NIH HHS/United States
GR  - R21 AG044712/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140424
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (tau Proteins)
RN  - BBX060AN9V (Hydrogen Peroxide)
SB  - IM
MH  - Alzheimer Disease/immunology/*therapy
MH  - Amyloid beta-Protein Precursor/genetics
MH  - Animals
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Fetus
MH  - Humans
MH  - Hydrogen Peroxide/metabolism
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunotherapy/*methods
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neurogenic Inflammation/immunology/*therapy
MH  - Neurons/*drug effects/physiology
MH  - Neuroprotective Agents
MH  - Oxidative Stress/drug effects
MH  - Primary Cell Culture
MH  - tau Proteins/genetics
PMC - PMC4293701
MID - NIHMS589089
EDAT- 2014/04/25 06:00
MHDA- 2015/04/17 06:00
PMCR- 2015/07/01
CRDT- 2014/04/25 06:00
PHST- 2014/03/15 00:00 [received]
PHST- 2014/03/19 00:00 [accepted]
PHST- 2014/04/25 06:00 [entrez]
PHST- 2014/04/25 06:00 [pubmed]
PHST- 2015/04/17 06:00 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - 10.1007/s10875-014-0020-9 [doi]
PST - ppublish
SO  - J Clin Immunol. 2014 Jul;34 Suppl 1(0 1):S80-5. doi: 10.1007/s10875-014-0020-9. 
      Epub 2014 Apr 24.